复制缺陷型5型腺病毒载体可在非人灵长类动物中引发持久的细胞免疫和体液免疫反应。
Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.
作者信息
Santra Sampa, Seaman Michael S, Xu Ling, Barouch Dan H, Lord Carol I, Lifton Michelle A, Gorgone Darci A, Beaudry Kristin R, Svehla Krisha, Welcher Brent, Chakrabarti Bimal K, Huang Yue, Yang Zhi-Yong, Mascola John R, Nabel Gary J, Letvin Norman L
机构信息
Division of Viral Pathogenesis, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, RE113, P. O. Box 15732, Boston, MA 02215, USA.
出版信息
J Virol. 2005 May;79(10):6516-22. doi: 10.1128/JVI.79.10.6516-6522.2005.
The magnitude and durability of immune responses induced by replication-defective adenovirus serotype 5 (ADV5) vector-based vaccines were evaluated in the simian-human immunodeficiency virus/rhesus monkey model. A single inoculation of recombinant ADV5 vector constructs induced cellular and humoral immunity, but the rapid generation of neutralizing anti-Ad5 antibodies limited the immunity induced by repeated vector administration. The magnitude and durability of the immune responses elicited by these vaccines were greater when they were delivered as boosting immunogens in plasmid DNA-primed monkeys than when they were used as single-modality immunogens. Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection.
在猿猴 - 人类免疫缺陷病毒/恒河猴模型中评估了基于复制缺陷型5型腺病毒（ADV5）载体的疫苗诱导的免疫反应的强度和持久性。单次接种重组ADV5载体构建体可诱导细胞免疫和体液免疫，但中和抗Ad5抗体的快速产生限制了重复载体给药诱导的免疫。当这些疫苗作为增强免疫原在经质粒DNA预免疫的猴子中给药时，所引发的免疫反应的强度和持久性比用作单一模式免疫原时更大。因此，在经DNA预免疫的受试者中给予基于ADV5的载体可能是这种疫苗模式产生长期免疫保护的优选用法。
Zotero 插件